Skip to main content
Biocartis Group NV logo

Biocartis Group NV — Investor Relations & Filings

Ticker · BCART ISIN · BE0974281132 LEI · 549300J4HOJL5KG8HY54 BR Manufacturing
Open in API
Filings indexed 636 across all filing types
Latest filing 2022-10-21 Earnings Release
Country BE Belgium
Listing BR BCART

About Biocartis Group NV

https://www.biocartis.com/en

Biocartis Group NV is a molecular diagnostics company that develops and commercializes its proprietary Idylla™ platform. This fully automated, sample-to-result system is designed to provide fast, easy, and actionable molecular diagnostic results, making advanced testing accessible to laboratories of any size. The company's primary focus is in the field of oncology, offering a menu of tests that support the diagnosis and treatment of various cancers, including lung, colorectal, melanoma, and breast cancer. Biocartis aims to enable personalized medicine for patients by providing universal access to molecular testing. The company also collaborates with pharmaceutical partners in the development of companion diagnostics.

Recent filings

Filing Released Lang Actions
221020 PR Q3 2022 Business Update_NL_FINAL.pdf
Earnings Release Classification · 98% confidence The document is titled 'PERSBERICHT VOORWETENSCHAP / GEREGLEMENTEERDE INFORMATIE' (Press Release for Information / Regulated Information) and explicitly announces the 'resultaten derde kwartaal 2022' (third quarter 2022 results). It provides key financial highlights for Q3 2022 (Product revenues, gross margin, operational cash burn) and updates the full-year outlook for 2022. This structure—a brief announcement focusing on key performance indicators and outlook adjustments following a specific reporting period—is characteristic of an Earnings Release (ER). It is not the comprehensive 'Interim Report' (IR) itself, but the initial announcement of the results. The document length (22,596 chars) is substantial, but the content is clearly framed as an 'announcement' of results rather than the full statutory report. Q3 2022
2022-10-21 Dutch
221010 PR Succesfull CB amendment_ENG_FINAL.pdf
Capital/Financing Update Classification · 99% confidence The document is a press release dated October 11, 2022, announcing the successful amendment of existing convertible bonds and offering an exchange into new convertible bonds, which involves changes to financing terms (maturity extension, coupon structure, security). This activity directly relates to the company's capital structure and fundraising efforts. Based on the definitions, this clearly falls under 'Capital/Financing Update' (CAP), as it details changes to outstanding debt instruments and associated financing arrangements.
2022-10-11 English
221010 PR Succesfull CB amendment_NL_FINAL.pdf
Capital/Financing Update Classification · 98% confidence The document is a press release dated October 11, 2022, titled "Biocartis kondigt succesvolle wijziging aan van haar bestaande converteerbare obligaties" (Biocartis announces successful amendment of its existing convertible bonds). It details changes to existing convertible bonds, the issuance of new convertible bonds, and an upcoming Extraordinary General Meeting (EGM) related to the recapitalization plan. This content directly relates to financing activities, capital structure changes (amendment/exchange of bonds), and debt instruments. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific corporate finance event.
2022-10-11 Dutch
EGM 2022 - 1L Receivables Board Report (NL) - Signed.pdf
Capital/Financing Update Classification · 95% confidence The document is a formal report titled "VERSLAG VAN DE RAAD VAN BESTUUR OVEREENKOMSTIG ARTIKELEN 7:179, EN 7:197 VAN HET WETBOEK VAN VENNOOTSCHAPPEN EN VERENIGINGEN" (Report of the Board of Directors pursuant to Articles 7:179 and 7:197 of the Code of Companies and Associations). This structure, referencing specific articles of Belgian corporate law (Wetboek van Vennootschappen en Verenigingen), and detailing a proposed capital increase via debt-for-equity swap (inbreng in natura van Senior Gewaarborgde Lening Schuldvorderingen) to be approved by an Extraordinary General Meeting (BAV), strongly indicates a document related to corporate governance and capital structure changes requiring shareholder approval. This aligns best with filings related to major corporate actions or governance disclosures. Since it is a detailed report from the Board justifying a major capital transaction (debt conversion into shares), it is not a simple announcement (RPA/RNS). It is a comprehensive report justifying a capital change. The closest fit among the provided options is 'Capital/Financing Update' (CAP) or potentially 'Governance Information' (CGR) due to the legal reporting structure, but the core subject is the proposed capital increase/restructuring. Given the focus on justifying the capital increase mechanism (inbreng in natura) and the associated debt restructuring, 'CAP' is the most appropriate primary classification, although it also contains elements of governance reporting required for such a transaction.
2022-09-27 Dutch
AR-Biocartis_Group-LM-CiK-26Sep2022-docusigned.pdf
Legal Proceedings Report Classification · 99% confidence The document is titled 'Verslag van de commissaris aan de buitengewone algemene vergadering inzake de inbreng in natura (artikel 7:197 WVV) en de uitgifte van aandelen (artikel 7:179 WVV)' (Commissioner's Report to the Extraordinary General Meeting regarding the contribution in kind and the issuance of shares). It details the auditor's review of a proposed capital increase via contribution in kind and share issuance, referencing specific articles of the Belgian Companies and Associations Code (WVV). This document is a formal report from an independent commissioner/auditor concerning a significant corporate action (capital restructuring/financing) presented to a general meeting. This aligns best with a document related to capital/financing activities, but specifically, it is a formal report/opinion related to a transaction, not a general financial report (10-K/IR) or a simple announcement (RPA/ER). Given the focus on capital structure changes, debt conversion, and share issuance, the 'Capital/Financing Update' (CAP) is relevant, but the document itself is a formal 'Report' or 'Opinion' related to that transaction, often required for shareholder votes at a General Meeting. Since it is a formal report by a commissioner regarding a capital transaction (inbreng in natura/uitgifte van aandelen), it is most closely related to 'Capital/Financing Update' (CAP) or potentially a specialized 'Audit Report/Information' (AR) if viewed strictly as an auditor's opinion. However, the core subject is the financing structure change. Since it is a formal report detailing the assessment of a capital transaction, and not just a simple announcement, and given the options, 'CAP' captures the subject matter best, although 'AR' (Audit Report/Information) is also plausible for the format. Given the context of 'inbreng in natura' and 'uitgifte van aandelen' which are financing activities, CAP is the most descriptive category for the *subject* of the report. If a specific 'Transaction Report' category existed, it would fit there. Between the provided options, 'CAP' (Capital/Financing Update) covers the substance of the transaction being reported on, even though the document format is a formal report/opinion.
2022-09-27 Dutch
EGM 2022 - Rights Offering Board Report (NL) - Signed.pdf
Management Reports Classification · 95% confidence The document is titled "VERSLAG VAN DE RAAD VAN BESTUUR OOREENKOMSTIG ARTIKELEN 7:179, 7:191 EN, VOOR ZOVEEL ALS NODIG EN TOEPASSELIJK, ARTIKEL 7:193 VAN HET WETBOEK VAN VENNOOTSCHAPPEN EN VERENIGINGEN" (Report of the Board of Directors pursuant to Articles 7:179, 7:191 and, where applicable, Article 7:193 of the Code of Companies and Associations). This structure strongly indicates a formal report prepared by the Board of Directors to justify a significant corporate action, specifically a capital increase and the suspension of pre-emptive rights, which must be presented to a shareholder meeting (BAV - Buitengewone Algemene Aandeelhoudersvergadering/Extraordinary General Meeting). The text details complex financing arrangements, debt restructuring, and proposed share issuance, which are typical components of a comprehensive management or board report accompanying a major corporate event requiring shareholder approval. Given the detailed justification required by Belgian corporate law articles cited (7:179, 7:191, 7:193) regarding capital changes and suspension of pre-emptive rights, this aligns best with a document providing management's detailed explanation of the proposed transaction and its implications, fitting the description of Management Reports (MDA) or a specific type of corporate governance/financing disclosure. Since it is a formal report justifying a major capital restructuring and suspension of shareholder rights, it is a comprehensive document explaining management's rationale, making MDA the most appropriate fit among the choices, although it shares characteristics with CAP (Capital/Financing Update) and CGR (Governance Information). However, the core function here is the Board's justification for the proposed transaction, which is the essence of an MDA.
2022-09-27 Dutch

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.